Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Case report

Cytarabine/idarubicin/tretinoin

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Wu H, et al. Report of PRPF19 as a novel partner of RARG and the recurrence of interposition-type fusion in variant acute promyelocytic leukemia. Hematological Oncology 41: 784-788, No. 4, Oct 2023. Available from: URL: http://dx.doi.org/10.1002/hon.3170 Wu H, et al. Report of PRPF19 as a novel partner of RARG and the recurrence of interposition-type fusion in variant acute promyelocytic leukemia. Hematological Oncology 41: 784-788, No. 4, Oct 2023. Available from: URL: http://​dx.​doi.​org/​10.​1002/​hon.​3170
Metadaten
Titel
Cytarabine/idarubicin/tretinoin
Lack of efficacy: case report
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-49508-y

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Sertraline

Case report

Rituximab

Case report

Paracetamol

Case report

Multiple drugs

Case report

Avatrombopag